Purpose:
To develop cumulative defect (Bebie’) curves for the Humphrey Matrix Frequency Doubling Technology (FDT) perimeter and evaluate its clinical utility for glaucoma, retina and neuro-ophthalmology patients.
Methods:
Data from testing both eyes of 261 normal controls subjects (ages 18 to 88) on the Humphrey Matrix using the 24-2 central visual field test procedure were used to generate cumulative defect Bebie’ curves. Normal subjects were required to have a normal eye examination, no history of ocular surgery other than uncomplicated cataract surgery, best corrected visual acuity of 20/40 or better, IOP less than 21 mm Hg, no systemic diseases, normal standard automated perimetry visual fields, refractive errors less than 5 D sphere and 2 D cylinder, and no medications known to affect visual field sensitivity. To adjust for normal sensitivity aging changes, all data was transformed to a 45 year old sensitivity equivalent. Cumulative defect curves were generated by ranking individual sensitivity values (55 locations) from highest to lowest.
Results:
The Humphrey Matrix 24-2 normal cumulative defect curve for normal right eyes (mean and 95% confidence limits) is presented in the figure below. Examples of diffuse, localized and combined visual field deficits will be presented for glaucoma, retinal disease, neuro-ophthalmologic conditions and artifactual test results. The Humphrey Matrix 24-2 normal cumulative defect curve for normal right eyes (mean and 95% confidence limits) is presented in the figure to the right. Examples of diffuse, localized and combined visual field deficits will be presented for glaucoma, retinal disease, neuro-ophthalmologic conditions and artifactual test results.
Conclusions:
The cumulative defect curve for the Humphrey Matrix represents a clinical data representation procedure that permits generalized (diffuse) and localized visual field losses for ocular and neurologic disorders.
Keywords: perimetry • visual fields • clinical research methodology